0001728117-24-000024.txt : 20240312 0001728117-24-000024.hdr.sgml : 20240312 20240312160117 ACCESSION NUMBER: 0001728117-24-000024 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240311 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gossamer Bio, Inc. CENTRAL INDEX KEY: 0001728117 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 475461709 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38796 FILM NUMBER: 24741977 BUSINESS ADDRESS: STREET 1: 3013 SCIENCE PARK CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 922-0718 MAIL ADDRESS: STREET 1: 3013 SCIENCE PARK CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 goss-20240311.htm 8-K goss-20240311
0001728117FALSE00017281172024-03-112024-03-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 11, 2024
GOSSAMER BIO, INC.
(Exact name of Registrant as Specified in Its Charter)
 
Delaware001-3879647-5461709
(State or Other Jurisdiction
of Incorporation)		(Commission File Number)(IRS Employer
Identification No.)
   
3013 Science Park Road
San Diego, California, 92121

(Address of Principal Executive Offices) (Zip Code)
(858) 684-1300
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading
Symbol(s)		 Name of each exchange on which registered
Common Stock, $0.0001 par value per share GOSS Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 11, 2024, pursuant to the amended and restated bylaws of Gossamer Bio, Inc. (the “Company”), the Board of Directors (the “Board”) of the Company appointed Skye Drynan to serve as a Class III director effective March 11, 2024, with an initial term expiring at the Company’s 2024 annual meeting of stockholders, and Steven Nathan, M.D. to serve as a Class I director effective March 11, 2024, with an initial term expiring at the Company’s 2025 annual meeting of stockholders. Since 2016, Ms. Drynan has served as the Founder, CEO and Creative Director of House of Skye, Ltd., a modern fashion house and a commerce, content and technology company. From 2008 to 2020, Ms. Drynan worked for Capital Group, where she was a Partner and a Senior BioPharma Analyst. Prior to joining Capital Group, she served as a Portfolio Manager and Global Head of Healthcare managing more than $1 billion in assets for Credit Suisse Asset Management, and she also held senior executive roles and was an investment professional, specializing in healthcare, at Lord, Abbett & Co. LLC, New Vernon Associates and Putnam Investments. Dr. Nathan is board certified in pulmonary diseases, critical care medicine and internal medicine. Since 1996, Dr. Nathan has served as the Medical Director of Inova Health System’s Advanced Disease Program and Lung Transplant Program, and since 2020, he has served as a Professor of Medical Education at the University of Virginia.

Pursuant to the Company’s non-employee director compensation program, each of Ms. Drynan and Dr. Nathan (i) will receive an annual cash retainer of $40,000 for service on the Board and (ii) was granted on the date of his or her appointment an option to purchase 230,000 shares of the Company’s common stock, which vests monthly over three years. Each of Ms. Drynan and Dr. Nathan has also entered into the Company’s standard form of Indemnification Agreement, the form of which was filed as Exhibit 10.14 to the Company's Form S-1, filed with the SEC on December 21, 2018, and incorporated herein by reference.

There is no arrangement or understanding between either Ms. Drynan or Dr. Nathan and any other person pursuant to which either Ms. Drynan or Dr. Nathan was appointed as a director. Neither Ms. Drynan nor Dr. Nathan is a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933, as amended. The Board has determined that each of Ms. Drynan and Dr. Nathan is an independent director in accordance with the listing requirements of the Nasdaq Global Select Market.

On March 12, 2024, the Company issued a press release announcing each of Ms. Drynan’s and Dr. Nathan’s appointment to the Board. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by this reference.


Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit NoDescription
99.1






 

2

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
  GOSSAMER BIO, INC.
    
Date: March 12, 2024
 By:/s/ Christian Waage
   Christian Waage
   Executive Vice President, Technical Operations & Administration

3
 EX-99.1 2 goss-20240312xxex991xnewdi.htm EX-99.1 Document

image_0.jpg
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan
to its Board of Directors

SAN DIEGO — (BUSINESS WIRE) — March 12, 2024 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors. Dr. Nathan is Medical Director of Inova’s Advanced Lung Disease Program and Lung Transplant Program and a Professor at the University of Virgina. Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.
Dr. Nathan brings to the Board a wealth of medical expertise, particularly in PH-ILD, which occurs when pulmonary hypertension occurs in association with interstitial lung disease, a broad array of conditions manifesting as scarring of the lungs. With only one approved therapeutic option in the US, and none in the EU, PH-ILD represents an indication of high unmet need. With Dr. Nathan’s guidance, Gossamer is poised to expand its clinical program for seralutinib to include PH-ILD, underscoring Gossamer’s commitment to addressing rare forms of pulmonary hypertension, or PH.
Ms. Drynan joins the Board with an extensive background in finance, investment, and entrepreneurship, specializing in the biotechnology industry. Her more than 25 years of experience in investing and advising public biotechnology companies and technology companies, in addition to navigating the complexities of the financial markets, will be invaluable as Gossamer continues to advance the development of seralutinib and position itself as a leader in the treatment of PH.
“The addition of Dr. Nathan to our Board signifies a pivotal moment in Gossamer’s evolution,” said Faheem Hasnain, Co-Founder, Chairman and CEO of Gossamer Bio. “It not only demonstrates our dedication to the PH community, but it also solidifies our standing in the field, as we broaden our focus beyond PAH.
“Ms. Drynan’s expertise will strengthen our ability to capitalize on opportunities and navigate the financial landscape. Her proven track record as a biotech analyst and her entrepreneurial drive undoubtably enhance our decision-making. Together these appointments elevate our strategic vision and position Gossamer for continued success."
Dr. Nathan is the Medical Director of Inova’s Advanced Lung Disease Program and Lung Transplant Program, a position he has held since 1996. He is also a Professor of Medical Education at the University of Virginia, a position he has held since 2020.


Dr. Nathan is board certified in pulmonary diseases, critical care medicine and internal medicine. As the author of more than 500 publications, Dr. Nathan is internationally recognized for his expertise in advanced lung diseases. He is co-editor of two books on idiopathic pulmonary fibrosis, or IPF, that provide pulmonologists and other healthcare workers with an up-to-date review of the background and advances in the field: Idiopathic Pulmonary Fibrosis and Guide to Clinical Management of Idiopathic Pulmonary Fibrosis. Dr. Nathan is a reviewer for multiple journals and is on the editorial board for the journal, Thorax. He has served on multiple committees, including FDA advisory boards, as well as steering committees for clinical trials in IPF and PH.
Dr. Nathan is a member of several professional medical associations, including the American Thoracic Society, the American College of Chest Physicians, and the International Society for Heart and Lung Transplantation. Dr. Nathan received an M.B.B.cH. from the University of Witwatersrand Medical School.
Ms. Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., which she founded in 2016. House of Skye is a modern fashion house and a commerce, content, and technology company, which has secured several patents covering artificial intelligence, technology, and design utility. She has secured significant investment and strategic partnerships for her new companies including a multi-level partnership with Accelerate360 and serves as a trusted advisor to tech and data companies including Nuda Foods, Vibely, VMD Ventures, and MNTN. Her entrepreneurial and creative achievements have been featured in Forbes, Bloomberg, Harper’s Bazaar, Glamour, and Elle, amongst other global media publications.
From 2008 to 2020, Ms. Drynan was a Partner and a Senior BioPharma Analyst for Capital Group, where she became one of the largest investors in biopharma, globally. Her vision and insights were critical to contributing to Capital Group’s more than $2 trillion in assets by leading a variety of biopharma investing syndicates in private offerings, IPOs and secondary offerings. Prior to joining Capital Group, she served as a Portfolio Manager and Global Head of Healthcare managing more than $1 billion in assets for Credit Suisse Asset Management. Ms. Drynan also held senior executive roles and was an investment professional, specializing in healthcare, at Lord Abbett, New Vernon Associates, and Putnam Investments. Ms. Drynan received a B.A. in Latin American Studies and Spanish from Wellesley College and served as a Research Assistant at the Whitehead Institute for Biomedical Research at MIT.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.
For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com

 EX-101.SCH 3 goss-20240311.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 goss-20240311_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 goss-20240311_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_0.jpg GRAPHIC begin 644 image_0.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 11, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Mar. 11, 2024
Entity Registrant Name GOSSAMER BIO, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38796
Entity Tax Identification Number 47-5461709
Entity Address, Address Line One 3013 Science Park Road
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 684-1300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol GOSS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001728117
Amendment Flag false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.gossamerbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports goss-20240311.htm goss-20240311.xsd goss-20240311_lab.xml goss-20240311_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "goss-20240311.htm": { "nsprefix": "goss", "nsuri": "http://www.gossamerbio.com/20240311", "dts": { "inline": { "local": [ "goss-20240311.htm" ] }, "schema": { "local": [ "goss-20240311.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "goss-20240311_lab.xml" ] }, "presentationLink": { "local": [ "goss-20240311_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.gossamerbio.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "goss-20240311.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "goss-20240311.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.gossamerbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001728117-24-000024-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001728117-24-000024-xbrl.zip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goss-20240311_htm.xml IDEA: XBRL DOCUMENT 0001728117 2024-03-11 2024-03-11 0001728117 false 8-K 2024-03-11 GOSSAMER BIO, INC. DE 001-38796 47-5461709 3013 Science Park Road San Diego CA 92121 858 684-1300 false false false false Common Stock, $0.0001 par value per share GOSS NASDAQ false